Imunon Halts COVID-19 Vaccine Program, Seeks Partner Due to Financial Struggles

Imunon has deprioritized its COVID-19 vaccine development program due to dwindling cash reserves, which fell below $5 million as of June 20252.

The company is actively seeking a partner to continue development of its IMNN-101 COVID-19 DNA vaccine candidate2.

IMNN-101 demonstrated safety and immunogenicity in a Phase 1 dose-escalation trial involving healthy adults previously vaccinated with other COVID-19 vaccines1.

The vaccine targets the Omicron XBB1.5 strain and showed protection comparable to mRNA vaccines in preclinical studies1.

Despite positive Phase 1 results, Imunon's financial constraints have led to a halt in further independent development of the COVID-19 vaccine project2.

Recent company communications, including the Q2 2025 financial results call, highlighted the strategic shift and ongoing efforts to secure new funding or collaboration for the vaccine division3.

Sources:

1. https://pmc.ncbi.nlm.nih.gov/articles/PMC11951686/

2. https://www.fiercebiotech.com/biotech/imunon-puts-covid-19-vaccine-ice-and-seeks-partner-amid-cash-crunch

3. https://www.globenewswire.com/news-release/2025/08/05/3127782/0/en/IMUNON-Recaps-Highlights-from-2025-Second-Quarter-Financial-Results-Conference-Call.html